Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Cancer Res. 2019 Feb 20;79(7):1587–1599. doi: 10.1158/0008-5472.CAN-18-2153

Figure 6.

Figure 6.

RIPK3 mediates tumor growth by I-MDSCs via CD4+IL17+ cells. A, Tumor volume in MC38 tumors injected with I-MDSCs, followed by GSK 872 treatment or anti-IL17A (D) compared with control group (n = 4). B and C, Percentage (B) and representative flow cytometry plots (C) of IL17-producing CD4 T cells in TILs from MC38 tumor-bearing mice from A. *, P < 0.05; ****, P < 0.0001; #, P < 0.06.